Shares of Inventurus Knowledge Solutions Limited rose by 1.73% to ₹1,460.10 on the National Stock Exchange by 12:26 PM on Friday. The stock previously reached an intraday high of ₹1,573.80, nearly a 10% increase from Thursday’s close of ₹1,435.30, before experiencing a sharp decline as selling pressure increased.
The company announced a definitive agreement after market hours on Thursday, April 23, in which IKS Health’s US subsidiary will acquire TruBridge, Inc. (NASDAQ: TBRG), a provider of revenue cycle management and electronic health record solutions for rural and community hospitals in the United States, for $26.25 per share in cash. This transaction values TruBridge at approximately $557 million.
The stock opened at ₹1,476.90 and has seen trading volumes of 3.335 million shares, amounting to ₹503.84 crore, highlighting unusual trading activity for a company with a free-float market capitalization of around ₹7,192 crore. Currently, sell orders represent 65% of the order book, while buy orders account for 35%, indicating that initial enthusiasm has encountered resistance at higher price levels.
To finance the acquisition, IKS plans to rely on approximately $600 million in new debt, assisted by a term loan backed by Citibank, JPMorgan Chase, and Deutsche Bank, leaving post-closing leverage at approximately three times the combined entity’s EBITDA. The acquisition is contingent upon approval from shareholders of both companies and US antitrust clearance, with expectations to close in the second quarter of fiscal year 2027.
According to management’s strategic rationale outlined in investor communications filed with BSE and NSE, the integration will combine TruBridge’s EHR platform—a “system of record” serving over 700 rural hospital clients—with IKS Health’s AI-driven care enablement platform, referred to as a “system of action.” The management team aims to achieve a combined EBITDA of approximately ₹3,000 crore by FY2030, compared to the current consolidated EBITDA of around ₹1,000 crore. The deal is anticipated to be accretive to earnings per share from the first full year following its closure.
IKS Health also identified a cross-selling potential of over $575 million within TruBridge’s existing client base, a significant component of its revenue growth strategy.
Despite the recent gains, the stock remains considerably below its 52-week high of ₹1,876 reached in June 2025, and is down 13.21% year-to-date, underperforming the Nifty 500, which has experienced a decline of 5.62% during the same timeframe.
Published on April 24, 2026
